Ofatumumab and bendamustine in previously treated chronic lymphocytic leukemia and small lymphocytic lymphoma (Q43469341)

23 November 2017

title

Ofatumumab and bendamustine in previously treated chronic lymphocytic leukemia and small lymphocytic lymphoma (English)

1 reference

chronic lymphocytic leukemia and small lymphocytic lymphoma

23 November 2017

0 references

0 references

1 reference

1 reference

Bruce D Cheson

1 reference

23 November 2017

Chaitra Ujjani

1 reference

23 November 2017

Pari Ramzi

1 reference

23 November 2017

Edmund Gehan

1 reference

23 November 2017

Hongkun Wang

1 reference

23 November 2017

Yiru Wang

1 reference

23 November 2017

publication date

6 August 2014

1 reference

23 November 2017

1 reference

23 November 2017

1 reference

23 November 2017

1 reference

23 November 2017

page(s)

915-920

1 reference

Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group

23 November 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.933217

Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.933217

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.933217

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.933217

Bendamustine compared to fludarabine as second-line treatment in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.933217

Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.933217

Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.933217

Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary struc

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.933217

Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.933217

Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.933217

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.933217

Revised response criteria for malignant lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.933217

Bendamustine in combination with ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.933217

Epstein-Barr virus infection and chronic lymphocytic leukemia: a possible progression factor?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.933217

Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.933217

10.3109/10428194.2014.933217

21 January 2018

Identifiers

DOI

1 reference

23 November 2017

1 reference